Faslodex FDA Approval History
FDA Approved: Yes (First approved April 25, 2002)
Brand name: Faslodex
Generic name: fulvestrant
Dosage form: Injection
Treatment for: Breast Cancer
Faslodex (fulvestrant) is an estrogen receptor antagonist indicated for the treatment of hormone receptor positive metastatic breast cancer.
Development timeline for Faslodex
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.